Healthtech funding in Q4 2016
European Healthtech startup funding raised during Q4 2016.
In Q4 2016, 103 European Healthtech companies closed 107 funding rounds and raised €477M in equity funding (excluding debt and grants), down 14.6% versus Q4 2015. Debt rounds added €18M. Ireland led by capital raised, and Bpifrance was the most active investor. Data as of 20 Nov 2026.
Equity funding
€477M
-14.6% vs Q4 2015 · excl. debt & grants · +€18M debt
Funding rounds
107
+33.8% vs Q4 2015
Companies
103
Top country
Ireland
Rank among sectors
#3
9.3% of sector funding
Debt financing
€18M
3.4% of total
Top-10 round share
63.8%
of disclosed capital
Funding by month
€ raised vs rounds, by monthHealthtech — funding by month, Q4 2016 — interactive chart.
Data table
| Funding | Rounds | |
|---|---|---|
| Oct | €257M | 43 |
| Nov | €153M | 36 |
| Dec | €110M | 28 |
Top countries
by € raisedHealthtech — top countries by capital, Q4 2016 — interactive chart.
Data table
| Healthtech — top countries by capital, Q4 2016 | |
|---|---|
| Ireland | €138M |
| France | €107M |
| Sweden | €75M |
| Russia | €50M |
| Switzerland | €41M |
| UK | €31M |
| Israel | €19M |
| Belgium | €15M |
Stage mix
by € raisedHealthtech — stage mix, Q4 2016 — interactive chart.
Data table
| Healthtech — stage mix, Q4 2016 | |
|---|---|
| Series A | €178M |
| Growth/Late | €93M |
| Early VC | €87M |
| Series B | €50M |
| Seed | €36M |
| Other | €33M |
| Grant | €25M |
| Debt | €18M |
Exits & M&A
7 Acquisition · 1 IPO8 exits · €42M disclosed.
| Genesort | Acquisition | Dec 2016 | €21M |
| Luck Genome | Acquisition | Oct 2016 | €11M |
| Linkcare | Acquisition | Oct 2016 | €5.0M |
| dariohealth | IPO | Nov 2016 | €4.6M |
Top deals
largest disclosed rounds in Q4 2016| Company | Stage | Date | Amount |
|---|---|---|---|
| Carrick Therapeutics | Series A | Oct 2016 | €86M |
| NaPopravku | Early VC | Dec 2016 | €46M |
| Genomics Medicine Ireland | Series A | Oct 2016 | €36M |
| Genfit | Growth/Late | Oct 2016 | €34M |
| BONESUPPORT | Growth/Late | Oct 2016 | €33M |
| OxThera | Other | Nov 2016 | €32M |
| NBE-Therapeutics | Series B | Nov 2016 | €19M |
| Corwave | Series B | Nov 2016 | €16M |
| Physidia | Growth/Late | Oct 2016 | €15M |
| Neuravi | Debt | Nov 2016 | €15M |
| Uromems | Series A | Nov 2016 | €12M |
| Univercells | Grant | Dec 2016 | €12M |
| Fortimedix | Series A | Oct 2016 | €11M |
| QGel | Growth/Late | Dec 2016 | €11M |
| Ava | Series A | Nov 2016 | €8.8M |
Top investors
most active in Q4 2016, by deal count- Bpifrance4 deals
- Amadeus Capital Partners3 deals
- High-Tech Gründerfonds (HTGF)3 deals
- Markeds modningsfonden - Market Maturation Fund3 deals
- Almi Invest2 deals
- Blue Ocean Ventures2 deals
- Boehringer Ingelheim Venture Fund2 deals
- Cambridge Enterprise2 deals
- Cambridge Innovation Capital2 deals
- Dendera Venture2 deals